Commentary

Video

Evolving and Current Standards of Care for HER2+ Early Breast Cancer

Author(s):

Vijayakrishna Gadi, MD, University of Illinois College of MedicineMegan Kruse, MD, of Cleveland Clinic

Vijayakrishna Gadi, MD, PhD, and Megan Kruse, MD, discuss how standard-of-care treatment has evolved for patients with HER2-positive early breast cancer.

Related Videos
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
Julia Foldi, MD, PhD
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Shruti Tiwari, MD
A panel of 3 experts on breast cancer
A panel of 3 experts on breast cancer
Samilia Obeng-Gyasi, MD, MPH,
Lauren E. Nye, MD
Debu Tripathy, MD
Related Content
OncLive On Air
May 30th 2024

Revisit Every OncLive On Air Episode From May 2024

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

FDA
May 29th 2024

Inavolisib Plus Palbociclib/Fulvestrant Earns FDA Priority Review for Advanced HR+/HER2–, PIK3CA+ Breast Cancer

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

James Ignatz-Hoover, MD, PhD
May 24th 2024

Weighing the Benefits and Limitations of CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma

Yen-Shen Lu, MD, PhD, chief, Division of Medical Oncology, Department of Oncology, National Taiwan University Hospital; clinical professor, Department of Internal Medicine, National Taiwan University College of Medicine
May 24th 2024

Ribociclib Plus Endocrine Therapy Demonstrates PFS Advantage in HR+/HER2– Advanced Breast Cancer